Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
cancer
cancer drugs
3
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
3
×
amgen
deals
eli lilly
europe blog main
europe top stories
indiana blog main
indiana top stories
novartis
roche
the column group
abbvie
allergan aesthetics
alzheimer's disease
astrazeneca
athira pharma
attralus
avapritinib
biontech
blueprint medicines
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
capmatinib
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
clinical trials
cobimetinib
covid-19
What
drug
3
×
cancer
medicines
acquisitions
address
approval
approves
biggest
bio
blueprint
build
buy
carries
ceo
certain
company’s
daniel
debut
designed
despite
dyne’s
family
fda
genetic
gilead
hardest
hit
hottest
hunters
ipo
latest
microbiome
moves
openly
o’day
pass
pipeline
proteins
ras
reels
Language
unset
3
×
Current search:
drug
×
unset
×
" san francisco top stories "
×
" cancer drugs "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
